7 March 2025 in Science Advances
Excessive neutrophil infiltration can exacerbate inflammation and tissue damage, contributing to conditions like autoimmune disorders and liver diseases. Mesenchymal stromal cells (MSCs) share homing mechanisms with neutrophils, showing promise for treating such diseases. However, ex vivo expanded MSCs often suffer from reduced homing efficiency due to the loss of essential ligands. Here, we engineer MSCs with P-selectin and E-selectin targeting peptides, assembling them into bispecific polyvalent structures using DNA self-assembly technology. This modification allows engineered MSCs to compete with chemotactic neutrophils for selectin binding sites on endothelial cells. In a mouse model of acute liver failure, engineered MSCs effectively home to the damaged liver and substantially inhibit excessive neutrophil infiltration. The combination of inhibiting neutrophil infiltration and the MSCs’ inherent therapeutic properties lead to superior therapeutic outcomes. Single-cell RNA sequencing reveals that engineered MSCs elevate the levels of Marco_macrophage, which have neutrophil-inhibitory effects. Our study offers a perspective for advancing MSC-based therapies in tissue repair.
13 November 2026 in Advanced Functional Materials
Proteolysis‐targeting chimeras (PROTACs) enable the selective degradation of disease‐relevant proteins by recruiting E3 ubiquitin ligases; however, their therapeutic potential is often limited by insufficient intracellular availability and inadequate target selectivity. Here, we report a modular DNA‐polymer architecture that integrates target‐specific DNA aptamer with a multivalent polymer scaffold. By anchoring multiple PROTAC molecules to a single polymer backbone, this architecture enables targeted delivery while increasing the amount of PROTAC delivered per cellular uptake event. To validate this design, we developed a construct utilizing the AS1411 aptamer and a copolymer backbone bearing multiple ARV771 molecules, which achieved significantly enhanced BRD4 degradation compared with its monovalent counterparts. Furthermore, in vivo studies demonstrated that the system exhibits prolonged systemic circulation, sustained tumor accumulation, and significant inhibition of tumor growth. Collectively, this modular DNA‐polymer frame‐work establishes a versatile strategy for the precision delivery and functional enhancement of PROTAC‐based degraders across diverse therapeutic contexts.